Literature DB >> 27630277

The Role of Cetuximab in the Induction of Anticancer Immune Response in Colorectal Cancer Treatment.

Lubos Holubec1, Jiri Polivka2, Martin Safanda3, Michal Karas4, Vaclav Liska5.   

Abstract

Monoclonal antibodies binding the epidermal growth factor receptor (EGFR), such as cetuximab or panitumumab, are widely used targeted therapeutics for the treatment of patients with colorectal cancer. The clinical significance of these drugs has so far been associated with combined chemotherapy or radiation. It has been shown that these treatment strategies have their clinical limitations and do not fully exploit the immunomodulatory effect of these drugs. In this review, we discuss the mechanisms of immunomodulation together with the anticancer immune response to the monoclonal antibodies targeted to the EGFR. The combination of anti-EGFR monoclonal antibodies with other immunotherapeutic treatment modalities certainly brings new opportunities for targeted therapy in patients with colorectal cancer. Copyright
© 2016 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.

Entities:  

Keywords:  Colorectal cancer; cetuximab; immune response; immunomodulation; review; targeted therapy

Mesh：

Substances：

Year:  2016        PMID： 27630277     DOI： 10.21873/anticanres.10985

Source DB:  PubMed          Journal:  Anticancer Res        ISSN： 0250-7005            Impact factor:   2.480


  15 in total

1.  MALDI-MSI of Immunotherapy: Mapping the EGFR-Targeting Antibody Cetuximab in 3D Colon-Cancer Cell Cultures.

Authors:  Xin Liu; Jessica K Lukowski; Colin Flinders; Seungil Kim; Rebecca A Georgiadis; Shannon M Mumenthaler; Amanda B Hummon
Journal:  Anal Chem       Date:  2018-12-07       Impact factor: 6.986

Review 2.  Immune Modulation of Head and Neck Squamous Cell Carcinoma and the Tumor Microenvironment by Conventional Therapeutics.

Authors:  Sayuri Miyauchi; Sangwoo S Kim; John Pang; Kathryn A Gold; J Silvio Gutkind; Joseph A Califano; Loren K Mell; Ezra E W Cohen; Andrew B Sharabi
Journal:  Clin Cancer Res       Date:  2019-02-27       Impact factor: 12.531

Review 3.  Immunotherapy for Colorectal Cancer: A Review of Current and Novel Therapeutic Approaches.

Authors:  Aaron J Franke; William Paul Skelton; Jason S Starr; Hiral Parekh; James J Lee; Michael J Overman; Carmen Allegra; Thomas J George
Journal:  J Natl Cancer Inst       Date:  2019-11-01       Impact factor: 13.506

4.  Peripheral White Blood Cell Subsets in Metastatic Colorectal Cancer Patients Treated with Cetuximab: The Potential Clinical Relevance.

Authors:  Ivana Z Matić; Branka Kolundžija; Ana Damjanović; Jelena Spasić; Davorin Radosavljević; Marija Đorđić Crnogorac; Nađa Grozdanić; Zorica D Juranić
Journal:  Front Immunol       Date:  2018-01-04       Impact factor: 7.561

5.  shRNA-induced silencing of Ras-related C3 botulinum toxin substrate 1 inhibits the proliferation of colon cancer cells through upregulation of BAD and downregulation of cyclin D1.

Authors:  You-Sheng Huang; Na Jie; Yi-Xin Zhang; Ke-Jian Zou; Yang Weng
Journal:  Int J Mol Med       Date:  2017-12-22       Impact factor: 4.101

Review 6.  LncRNAs as Regulators of Autophagy and Drug Resistance in Colorectal Cancer.

Authors:  Mercedes Bermúdez; Maribel Aguilar-Medina; Erik Lizárraga-Verdugo; Mariana Avendaño-Félix; Erika Silva-Benítez; Cesar López-Camarillo; Rosalío Ramos-Payán
Journal:  Front Oncol       Date:  2019-10-02       Impact factor: 6.244

Review 7.  Immunotherapy in colorectal cancer: Available clinical evidence, challenges and novel approaches.

Authors:  Joseph Tintelnot; Alexander Stein
Journal:  World J Gastroenterol       Date:  2019-08-07       Impact factor: 5.742

Review 8.  Immune Checkpoint Inhibition in Colorectal Cancer: Microsatellite Instability and Beyond.

Authors:  Romain Cohen; Benoît Rousseau; Joana Vidal; Raphaël Colle; Luis A Diaz; Thierry André
Journal:  Target Oncol       Date:  2020-02       Impact factor: 4.864

9.  Rethink of EGFR in Cancer With Its Kinase Independent Function on Board.

Authors:  Rintu Thomas; Zhang Weihua
Journal:  Front Oncol       Date:  2019-08-23       Impact factor: 6.244

10.  EGFR Alterations Influence the Cetuximab Treatment Response and c-MET Tyrosine-Kinase Inhibitor Sensitivity in Experimental Head and Neck Squamous Cell Carcinomas.

Authors:  Györgyi A Nelhűbel; Mihály Cserepes; Balázs Szabó; Dóra Türk; Adél Kárpáti; István Kenessey; Erzsébet Rásó; Tamás Barbai; Zita Hegedűs; Viktória László; Bálint Szokol; Judit Dobos; László Őrfi; József Tóvári
Journal:  Pathol Oncol Res       Date:  2021-05-03       Impact factor: 3.201
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.